Targeting Interleukin-6 in Rheumatoid Arthritis

How early in the course of rheumatoid arthritis does the excess cardiovascular risk appear?

(2012) Anne M Kerola et al.   ANNALS OF THE RHEUMATIC DISEASES

Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions

(2012) Josef S Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

A phase II, double-blind, randomised, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis with an inadequate response to methotrexate

(2012) P Mease et al.   ANNALS OF THE RHEUMATIC DISEASES

Tocilizumab – A novel therapy for non-organ-specific autoimmune diseases

(2012) Lisa Kaly et al.   BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY

The role of tocilizumab in the management of rheumatoid arthritis

(2012) Zoe Ash et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Assessing the safety of biologic agents in patients with rheumatoid arthritis

(2012) A. Rubbert-Roth   RHEUMATOLOGY

Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica

(2012) S. Unizony et al.   ARTHRITIS CARE & RESEARCH

Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study

(2011) Yusuf Yazici et al.   ANNALS OF THE RHEUMATIC DISEASES

Inflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage

(2011) S. I. Grivennikov et al.   ANNALS OF THE RHEUMATIC DISEASES

Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register

(2011) M. M. Soliman et al.   ANNALS OF THE RHEUMATIC DISEASES

2011 ACR/ARHP Annual Scientific Meeting Late-Breaking Abstracts

(2011)   ARTHRITIS AND RHEUMATISM

The Unholy Trinity: Inflammation, Cytokines, and STAT3 Shape The Cancer Microenvironment

(2011) Ning Li et al.   CANCER CELL

Tocilizumab treatment for neuro-Behcet's disease, the first report

(2011) Lee S. Shapiro et al.   CLINICAL NEUROLOGY AND NEUROSURGERY

Evaluating disease activity in rheumatoid arthritis: Which composite index is best? A systematic literature analysis of studies comparing the psychometric properties of the DAS, DAS28, SDAI and CDAI

(2011) Cécile Gaujoux-Viala et al.   JOINT BONE SPINE

A case of Behçet’s disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab

(2011) Toru Hirano et al.   Modern Rheumatology

Complete remission of myeloperoxidase-anti-neutrophil cytoplasmic antibody-associated crescentic glomerulonephritis complicated with rheumatoid arthritis using a humanized anti-interleukin 6 receptor antibody

(2011) K. Sumida et al.   RHEUMATOLOGY

Therapeutic effect of tocilizumab on two patients with polymyositis

(2011) M. Narazaki et al.   RHEUMATOLOGY

Clinical results for tocilizumab over one year in the clinical setting as assessed by CDAI (clinical disease activity index): CRP at week 12 and MMP-3 at week 24 are predictive factors for CDAI

(2011) Atsushi Kaneko et al.   RHEUMATOLOGY INTERNATIONAL

Integrated safety in tocilizumab clinical trials

(2011) Michael H Schiff et al.   ARTHRITIS RESEARCH & THERAPY

Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA)

(2010) G. R. Burmester et al.   ANNALS OF THE RHEUMATIC DISEASES

Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: The role of acute-phase reactants

(2010) Josef S. Smolen et al.   ARTHRITIS AND RHEUMATISM

Tocilizumab in systemic lupus erythematosus: Data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study

(2010) Gabor G. Illei et al.   ARTHRITIS AND RHEUMATISM

Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: Results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structu

(2010) Joel M. Kremer et al.   ARTHRITIS AND RHEUMATISM

Comparison of composite disease activity indices for rheumatoid arthritis

(2010) Toshihiro Matsui et al.   Modern Rheumatology

The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab

(2010) Y. Shima et al.   RHEUMATOLOGY

Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials

(2010) L. Campbell et al.   RHEUMATOLOGY

Tocilizumab in refractory adult Still's disease

(2010) Xavier Puéchal et al.   ARTHRITIS CARE & RESEARCH

The role of Interleukin 6 in the pathophysiology of rheumatoid arthritis

(2010) Srinivasan Srirangan et al.   Therapeutic Advances in Musculoskeletal Disease

Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study

(2009) G. Jones et al.   ANNALS OF THE RHEUMATIC DISEASES

Demyelinating events in rheumatoid arthritis after drug exposures

(2009) S. Bernatsky et al.   ANNALS OF THE RHEUMATIC DISEASES

Total cholesterol and LDL levels decrease before rheumatoid arthritis

(2009) E. Myasoedova et al.   ANNALS OF THE RHEUMATIC DISEASES

Leukoencephalopathy with Cognitive Impairment following Tocilizumab for the Treatment of Rheumatoid Arthritis (RA)

(2009) Katsuya Kobayashi et al.   INTERNAL MEDICINE

Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study

(2008) N Nishimoto et al.   ANNALS OF THE RHEUMATIC DISEASES

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

(2008) P. Emery et al.   ANNALS OF THE RHEUMATIC DISEASES

Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study

(2008) Mark C. Genovese et al.   ARTHRITIS AND RHEUMATISM

Atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus

(2008) Sahena Haque et al.   CURRENT OPINION IN LIPIDOLOGY

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial

(2008) Josef S Smolen et al.   LANCET

Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy

(2008) Norihiro Nishimoto et al.   Modern Rheumatology